Taking stock of the drug industry, from the lab to the medicine chestFebruary 14, 2024Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Chip Somodevilla/Getty Images STAT+ | FTC to probe the role of middlemen in worsening drug shortage crisis The FTC wants to know whether group purchasing organizations and wholesalers are misusing their market power. By Ed Silverman and John Wilkerson STAT+ | Biotech launches with $135 million for Vertex-competing pain medicine Latigo Biotherapeutics launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals. By Allison DeAngelis STAT+ | Leaked version of EFTA-India free trade deal sparks alarm over access to medicines The leaked language in a draft agreement suggests changes would have to be made to India's patent and regulatory laws. By Ed Silverman David J. Phillip/AP STAT+ | Opinion: A year in, the U.S. is still not taking advantage of lower-cost biosimilars for Humira Medicare beneficiaries and taxpayers could have saved close to $3 billion if more patients were getting Humira biosimilars. By Juliana M. Reed Opinion: The health care system is ignoring world's most promising approach to preventing cardiovascular disease The "next breakthrough" to fight hypertension already exists. It's called the polypill. Why isn't the U.S. health care system embracing it? By Arthur L. Kellermann More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2024, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments